

## References - Diagnostic usefulness of indocyanine green angiography (ICGA) in age-related macular degeneration (AMD)

1. Congdon NG, Friedman DS, Lietman T. Important Causes of Visual Impairment in the World Today. *JAMA*. 2003;290(15):2057-2060.
2. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. *Arch Ophthalmol*. 2004;122:564-572.
3. Bressler NM. Age-Related Macular Degeneration Is the Leading Cause of Blindness. *JAMA*. 2004;291(15):1900-1901.
4. Alfredo Pece, Claudio Azzolini, Maurizio Battaglia Parodi, Ferdinando Bottoni, Paola Danzi, Simone Donati, Ugo Introini, Vincenzo Pucci, Francesco Semeraro, and Francesco Viola. Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab. *Expert Review of Ophthalmology*. 2012;7(3):219-225.
5. Chappelov AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. *Drugs*. 2008;68(8):1029-36.
6. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. *Mayo Clin Proc*. 2012;87(1):77-88.
7. Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. *Drugs Aging*. 2007; 24(8):643-62.
8. Agarwal A, Rhoades WR, Hanout M, Soliman MK, Sarwar S, Sadiq MA, Sepah YJ, Do DV, Nguyen QD. Management of neovascular age related macular degeneration: current state-of-the art care optimizing visual outcomes and therapies in development. *Clini Ophthamol*. 2015 Jun;9:1001-15.
9. Shoughy SS, Kozak I. Selective and complementary use of Optical Coherence Tomography and Fluorescein Angiography in retinal practice. *Eye Vis (Lond)*. 2016;17;3:26.
10. Hope-Ross M, Yannuzzi LA, Gragoudas ES, TFyer DR, Slakter JS, Sorenson JA, Krupsky S, Orlock DA, Puliafito CA. Adverse reactions due to indocyanine green. *Ophthalmology*. 1994;101:529-533.
11. Cherrick GR, Stein SW, Leevy CM, Davidson CS. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. *J Clin Invest*. 1960 Apr;39:592-600.
12. Baker KJ. Binding of sulfobromophthalein (BSP) sodium and indocyanine green (ICG) by plasma alpha-1 lipoproteins. *Proc Soc Exp Biol Med*. 1966 Aug-Sep;122(4):957-63.
13. Brown N, Strong R. Infrared fundus angiography. *Br J Ophthalmol*. 1973 Oct;57(10):797-802.
14. Fineman MS, Maguire JJ, Fineman SW, Benson WE. Safety of indocyanine green angiography during pregnancy. *Arch Ophthalmol*. 2001; 119:353-355.
15. Guyer DR and Yannuzzi LA. Occult choroidal neovascularization. In Flower RW. *Indocyanine green angiography*. Yannuzzi LA, Flower RW, Slakter JS. Ed. Mosby. St. Louis, Missouri. 199:157-180.
16. Guyer DR, Puliafito CA, Mones JM, Friedman E, Chang W, Verdooner SR. Digital indocyanine-green angiography in chorioretinal disorders. *Ophthalmology*. 1992 Feb;99(2):287-91.
17. Yannuzzi LA, Slakter JS, Sorenson JA, Guyer DR, Orlock DA. Digital indocyanine green videoangiography and choroidal neovascularization. *Retina*. 1992;12(3):191-223.
18. Kogure K, David NJ, Yamanouchi U, Choromokos E. Infrared absorption angiography of the fundus circulation. *Arch Ophthalmol*. 1970 Feb;83(2):209-14.
19. Flower RW. Injection technique for indocyanine green and sodium fluorescein dye angiography of the eye. *Invest Ophthalmol*. 1973; 12:881-895.
20. Desmettre T, Devoisselle JM, Mordon S. Fluorescence properties and metabolic features of indocyanine green as related to angiography. *Surv Ophthalmol*. 2000; 45:15-27.
21. Obana A, Miki T, Hayashi K, Takeda M, Kawamura A, Mutoh T, Harino S, Fukushima I, Komatsu H, Takaku Y. Survey of complications of indocyanine green angiography in Japan. *Am J Ophthalmol*. 1994;118:749-753.
22. Cohen SY, Dubois L, Quentel G, Gaudric A. Is indocyanine green angiography still relevant? *Retina*. 2011 Feb;31(2):209-21.
23. Yannuzzi LA, Slakter JS, Sorenson JA, Guyer DR, Orlock DA. Digital indocyanine green videoangiography and choroidal neovascularization. *Retina*. 1992;12:191-223.
24. Hayashi K, Hasegawa Y, Tokoro T, De Laey JJ. Value of indocyanine green angiography in the diagnosis of occult choroidal neovascular membrane. *Jpn J Clin Ophthalmol*. 1988;42:827-829.
25. Hayashi K, Hasegawa Y, Tokoro T, De Laey JJ. Clinical application of indocyanine green angiography to occult choroidal neovascularisation. *Jpn J Clin Ophthalmol*. 1989;43:57-65.
26. Sorenson JA, Yannuzzi LA, Slakter JS, Guyer DR, Ho AC, Orlock DA. A pilot study of digital indocyanine green videoangiography for recurrent occult choroidal neovascularization in age-related macular degeneration. *Arch Ophthalmol*. 1994;112:473-479.
27. Slakter JS, Yannuzzi LA, Sorenson JA, Guyer DR, Ho AC, Orlock DA. A pilot study of indocyanine green videoangiography-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration. *Arch Ophthalmol*. 1994;112:465-472.
28. Yannuzzi LA, Negrao S, Iida T et al. Retinal angiomatous proliferation in age-related macular degeneration. *Retina* 2001;21:416-434.
29. Kuhn D, Meunier I, Soubrane G, Coscas G. Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelium detachments. *Arch Ophthalmol*. 1995;113:1392-1398.
30. Freund KB, Ho IV, Barbazetto IA, Koizumi H, Laud K, Ferrara D, Matsumoto Y, Sorenson JA, Yannuzzi L. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. *Retina*. 2008;28:201-211.

31. Shiraga F, Ojima Y, Matsuo T, Takasu I, Matsuo N. Feeder vessel photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Ophthalmology*. 1998;105:662-669.
32. Flower RW. Experimental studies of indocyanine green dye-enhanced photocoagulation of choroidal neovascularization feeder vessels. *Am J Ophthalmol*. 2000;129:501-512.
33. Desatnik H, Treister G, Alhalel A, Krupsky S, Moisseiev J. ICGA-guided laser photocoagulation of feeder vessels of choroidal neovascular membranes in age-related macular degeneration. *Indocyanine green angiography. Retina* 2000; 20:143-150.
34. Lafaut BA, Bartz-Schmidt KU, Vanden Broecke C, Aisenbrey S, De Laey JJ, Heimann K. Clinicopathological correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. *Br J Ophthalmol*. 2000;84:239-243.
35. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. *Arch Ophthalmol*. 2001;119:198-207.
36. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization verteporfin in photodynamic therapy report 2. *Am J Ophthalmol*. 2001;131:541-560.
37. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2006;355:1419-1431.
38. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age related macular degeneration. *N Engl J Med*. 2006;355:1432-1444.
39. Arias L. Treatment of retinal pigment epithelial detachment with antiangiogenic therapy. *Clin Ophthalmol*. 2010;4:369-374.
40. Gass JD, Agarwal A, Lavina AM, Tawansy KA. Focal inner retinal hemorrhages in patients with drusen: an early sign of occult choroidal neovascularization and chorioretinal anastomosis. *Retina*. 2003;23:741-751.
41. Matsumoto H, Sato T, Kishi S. Tomographic features of intraretinal neovascularization in retinal angiomatous proliferation. *Retina* 2010;30:425-430.
42. Spaide RF. Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration. *Am J Ophthalmol*. 2009;147:644-652.
43. Keane PA, Sadda SR. Imaging chorioretinal vascular disease. *Eye (Lond)*. 2010;24:422-427.
44. Arnold JJ, Quaranta M, Soubrane G, Sarks SH, Coscas G. Indocyanine green angiography of drusen. *Am J Ophthalmol*. 1997;124:344-356.
45. Chang AA, Guyer DR, Orlock DR, Yannuzzi LA. Age-dependent variations in the drusen fluorescence on indocyanine green angiography. *Clin Experiment Ophthalmol*. 2003;31:300-304.
46. Quaranta M, Buglione M, Lo Schiavo Elia R, Coscas G, Soubrane G. Indocyanine green angiography of basal laminar drusen in the retinal pigment epithelium associated with vitelliform macular degeneration. *J Fr Ophtalmol*. 1998;21:185-190.
47. Arnold JJ, Sarks SH, Killingsworth MC, Sarks JP. Reticular pseudodrusen. A risk factor in age-related maculopathy. *Retina*. 1995;15:183-191.
48. Smith RT, Sohrab MA, Busuioc M, Barile G. Reticular macular disease. *Am J Ophthalmol*. 2009;148:733-743.
49. Giani A, Pellegrini M, Carini E, Peroglio Deiro A, Bottoni F, Staurengi G. The dark atrophy with indocyanine green angiography in Stargardt disease. *Invest Ophthalmol Vis Sci*. 2012 Jun 26;53(7):3999-4004.
50. Guyer DR, Yannuzzi LA, Slakter JS, et al. Classification of choroidal neovascularization by digital indocyanine green videoangiography. *Ophthalmology*. 1996;103:2054-60.
51. Stanga PE, Lim JJ, Hamilton P. Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update. *Ophthalmology*. 2003 Jan;110(1):15-21.
52. Guyer DR, Yannuzzi LA, Ladas I, et al. Indocyanine green guided laser photocoagulation of focal spots at the edge of plaques of choroidal neovascularization. *Arch Ophthalmol*. 1996;114:693-7.
53. Kim H, Lee SC, Kim SM, Lee JH, Koh HJ, Kim SS, Byeon SH, Kim M, Lee Cs. Identification of underlying causes of spontaneous submacular haemorrhage by indocyanine green angiography. *Ophthalmologica*. 2015;233(3-4):146-54.
54. Hoang QV, Gallego-Pinazo R, Yannuzzi LA. Long-term follow-up of acute zonal occult outer retinopathy. *Retina*. 2013 Jul-Aug;33(7):1325-7.
55. Sorenson JA, Yannuzzi LA, Slakter JS, Guyer DR, Ho AC, Orlock DA. A pilot study of digital indocyanine green videoangiography for recurrent occult choroidal neovascularization in age-related macular degeneration. *Arch Ophthalmol*. 1994 Apr;112(4):473-9.
56. Coscas G. Chapter III: Age-Related Macular Degeneration. In: Atlas of indocyanine green angiography fluorescein angiography, ICG angiography and OCT correlations. Coscas G. pp 118. Ed. Elsevier September 2005. ISBN: 2-84299-729-8.
57. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. *Am J Ophthalmol*. 1993 Jun;115(6):786-91.
58. Haddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. *Br J Ophthalmol*. 2002 Jun;86(6):663-9.
59. Gass JD. Serous retinal pigment epithelial detachment with a notch: a sign of occult choroidal neovascularization. 1984. *Retina*. 2003 Dec;23(6 Suppl):205-20.
60. Yannuzzi LA, Hope-Ross M, Slakter JS, Guyer DR, Sorenson JA, Ho AC, Sperber DE, Freund KB, Orlock DA. Analysis of vascularized pigment epithelial detachments using indocyanine green videoangiography. *Retina*. 1994;14(2):99-113.

61. Tan A, Simhaee D, Balaratnasingam C, Dansingani K, Yannuzzi L. A perspective on the nature and frequency of pigment epithelial detachment. *Am J Ophthalmol*. 2016 Dec;172:13-27.
62. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. *Retina*. 2001; 21: 416-434.
63. Parodi MB, Iacono P, Menchini F, Sheth S, Polini G, Pittino R, Bandello F. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. *Acta Ophthalmol*. 2013 May;91(3):267-73.
64. Yannuzzi LA. Degeneration: age-related macular degeneration. In: *The Retinal Atlas*. Philadelphia, PA: Saunders; 2010.
65. Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatous proliferation or type 3 neovascularization [editorial]. *Retina*. 2008;28:375-384.
66. Massaccesi AL, Sacchi L, Bergamini F, Bottoni F. The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization. *Graefes Arch Clin Exp Ophthalmol*. 2008;246:89-92.
67. Kuhn D, Meunier I, Soubrane G, Coscas G. Imaging of chorioretinal anastomoses in vascularised retinal pigment epithelial detachments. *Arch Ophthalmol*. 1995;113:1392-1398.
68. Querques G, Querques L, Forte R, Massamba N, Blanco R, Souied EH. Precursors of type 3 neovascularization: A Multimodal Imaging Analysis. *Retina*. 2013 Jun;33(6):1241-8.
69. Hartnett ME, Weiter JJ, Staurengli G, et al. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. *Ophthalmology*. 1996;103:2042-2053.
70. Bottoni F, Massaccesi A, Cigada M, et al. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. *Arch Ophthalmol*. 2005;123: 1644-1650.
71. Bressler NM. Retinal anastomosis to choroidal neovascularization: a bum rap for a difficult disease. *Arch Ophthalmol*. 2005;123:1741-1743.
72. Ghazi NG, Knape RM, Kirk TQ, Tiedeman JS, Conway BP. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation. *Retina*. 2008 May;28(5):689-95.
73. Axel-Siegel R, Bourla D, Priel E, Yassur Y, Weinberger D. Angiographic and flow patterns of retinal choroidal anastomoses in age-related macular degeneration with occult choroidal neovascularization. *Ophthalmology*. 2002 Sep;109(9):1726-36.
74. Gross NE, Aizman A, Brucker A, Klancknik JM Jr, Yannuzzi LA. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. *Retina*. 2005;25(6):713-718.
75. Campa C, Harding SP, Pearce IA, Beare NA, Briggs MC, Heimann H. Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. *Eye (Lond)*. 2010 Oct;24(10):1585-9.
76. Koizumi H, Iida T, Saito M, Nagayama D, Maruko I. Choroidal circulatory disturbances associated with retinal angiomatous proliferation on indocyanine green angiography. *Graefes Arch Clin Exp Ophthalmol*. 2008;246(4):515-520.
77. McBain VA, Kumari R, Townend J, Lois N. Geographic atrophy in retinal angiomatous proliferation. *Retina*. 2011; 31(6):1043-1052.
78. Kim JH, Kim JR, Kang SW, Kim SJ, Ha HS. Thinner Choroid and Greater Drusen Extent in Retinal Angiomatous Proliferation than in Typical Exudative Age-Related Macular Degeneration. *J Ophthalmol*. 2013;155:743-749.
79. Mendis R, Leslie T, McBain VA, Lois N. Combined therapy for retinal angiomatous proliferation with intravitreal triamcinolone and argon laser photocoagulation. *Br J Ophthalmol*. 2008;92:1154-1156.
80. Boscia F, Furino C, Sborgia L, Reibaldi M, Sborgia C. Photodynamic therapy for retinal angiomatous proliferation and pigment epithelium detachment. *Am J Ophthalmol*. 2004; 138:1077-1079.
81. Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia G. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. *Graefes Arch Clin Exp Ophthalmol*. 2006;244: 1224-1232.
82. Kuroiwa S, Arai J, Gaun S, Iida T, Yoshimura N. Rapidly progressive scar formation after transpupillary thermotherapy in retinal angiomatous proliferation. *Am J Ophthalmol*. 2003;23:417-420.
83. Hemeida TS, Keane PA, Dustin L, Sadda SR, Fauzi AA. Long-term visual and anatomic outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. *Br J Ophthalmol*. 2009;6:701-705.
84. Gharbiya M, Allievi F, Recupero V, Martini D, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results. *Retina*. 2009 Jun;29(6):740-9.
85. Rouvas AA, Papakostas TD, Ladas ID. Ranibizumab for retinal angiomatous proliferation. *Graefes Arch Clin Exp Ophthalmol*. 2009 Dec;247(12):1719-20.
86. Engelbert M, Zweifel SA, Freund KB. "Treat and extend" dosing of intravitreal anti-vascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. *Retina*. 2009 Nov-Dec;29(10):1424-31.
87. Montero JA, Fernandez MI, Gomez-Ulla F, Ruiz-Moreno JM. Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III. *Eur J Ophthalmol*. 2009;19:448-451.
88. Konstantinidis L, Mameletzi E, Mantel I, Pournovas JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). *Graefes Arch Clin Exp Ophthalmol*. 2009;9:1165-1171.
89. Meyerle CB, Freund KB, Iturralde D, et al. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. *Retina*. 2007;27:451-457.
90. Hemeida TS, Keane PA, Dustin L, Sadda SR, Fawzi AA. Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. *Br J Ophthalmol*. 2010 Jun;94(6):701-5.
91. Gupta B, Jyothi S, Sivaprasad S. Current treatment options for retinal angiomatous proliferans (RAP). *Br J Ophthalmol*. 2010

92. George S, Cooke C, Chakravarthy U. Exudative AMD subtypes and eligibility for treatment with ranibizumab. *Eye (Lond)*. 2010 Jul;24(7):1247-51.
93. Atmani K, Voigt M, Le Tien V, et al. Ranibizumab for retinal angiomatic proliferation in age-related macular degeneration. *Eye*. 2010;24:1193-1198.
94. Querques G, Rousseau A, Forte R, et al. Longitudinal anatomical response of retinal-choroidal anastomosis to anti-vascular endothelial growth factor therapy. *Retina*. 2012;32:458-467.
95. Hufendiek K, Hufendiek K, Panagakis G, Helbig H, Gamulescu MA. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatic proliferation. *Int Ophthalmol*. 2012 Jun;32(3):259-68.
96. Kramann CA, Schöpfer K, Lorenz K, Zwiener I, Stoffelns BM, Pfeiffer N. Intravitreal ranibizumab treatment of retinal angiomatic proliferation. *Acta Ophthalmol*. 2012 Aug;90(5):487-91.
97. Hsu TK, Liu JH, Lei J, Chao HM. Retinal angiomatic proliferation responds safely to a double dose (1.0 mg) of ranibizumab. *Clin Exp Optom*. 2013 Jan;96(1):112-6.
98. Krebs I, Krepler K, Stolba U, Goll A, Binder S. Retinal angiomatic proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone. *Graefes Arch Clin Exp Ophthalmol*. 2008 Feb;246(2):237-43.
99. Bakri SJ, Ekdawi NS. Intravitreal triamcinolone and bevacizumab combination therapy for refractory choroidal neovascularization with retinal angiomatic proliferation. *Eye (Lond)*. 2008 Jul;22(7):978-80.
100. Saito M, Shiragami C, Shiraga F, Nagayama D, Iida T. Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatic proliferation. *Am J Ophthalmol*. 2008 Dec;146(6):935-41.e1.
101. Montero JA, Ruiz-Moreno JM, Sanabria MR, Fernandez-Munoz M. Efficacy of intravitreal and periocular triamcinolone associated with photodynamic therapy for treatment of retinal angiomatic proliferation. *Br J Ophthalmol*. 2009 Feb;93(2):166-70.
102. Rouvas AA, Papakostas TD, Vavvas D, Vergados I, Moschos MM, Kotsolis A, Ladas ID. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatic proliferation: a prospective study. *Retina*. 2009 Apr;29(4):536-44.
103. Shima C, Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Tano Y. One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol*. 2009 Jul;247(7):899-906.
104. Lo Giudice G, Gismondi M, De Belvis V, Cian R, Tavolato M, Galan A. Single-session photodynamic therapy combined with intravitreal bevacizumab for retinal angiomatic proliferation. *Retina*. 2009 Jul-Aug;29(7):949-55.
105. Saito M, Shiragami C, Shiraga F, Kano M, Iida T. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatic proliferation. *Am J Ophthalmol*. 2010 Mar;149(3):472-81.
106. Sahu AK, Narayanan R. Intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy (PDT), and intravitreal triamcinolone with PDT for the treatment of retinal angiomatic proliferation. *Retina*. 2010 Jun;30(6):981.
107. Viola F, Mapelli C, Villani E, Tresca Carducci F, Vezzola D, Ratiglia R. Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatic proliferation. *Eye (Lond)*. 2010 Aug;24(8):1344-51.
108. Lee MY, Kim KS, Lee WK. Combination therapy of ranibizumab and photodynamic therapy for retinal angiomatic proliferation with serous pigment epithelial detachment in Korean patients: twelve-month results. *Retina*. 2011 Jan;31(1):65-73.
109. Nakano S, Honda S, Oh H, Kita M, Negi A. Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatic proliferation. *Clin Ophthalmol*. 2012;6:277-82.
110. Saito M, Iida T, Kano M. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatic proliferation. *Am J Ophthalmol*. 2012 Mar;153(3):504-514.
111. Lee MY, Kim KS, Lee WK. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatic proliferation. *Am J Ophthalmol*. 2012 May;153(5):1004-5; author reply 1005.
112. Rouvas AA, Chatziralli IP, Theodosiadis PG, Moschos MM, Kotsolis AI, Ladas ID. Long-term results of intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy, and intravitreal triamcinolone with photodynamic therapy for the treatment of retinal angiomatic proliferation. *Retina*. 2012 Jun;32(6):1181-9.
113. Shirakata Y, Shiragami C, Yamashita A, Nitta E, Fujiwara A, Shiraga F. One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatic proliferation. *Jpn J Ophthalmol*. 2012 Nov;56(6):599-607.
114. Saito M, Iida T, Kano M. Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatic proliferation. *Jpn J Ophthalmol*. 2013 Mar;57(2):211-20.
115. Forooghian F, Cukras C, Chew EY. Retinal angiomatic proliferation complicated by pigment epithelial tear following intravitreal bevacizumab treatment. *Can J Ophthalmol*. 2008 Apr;43(2):246-8.
116. Gutfleisch M, Heimes B, Schumacher M, Dietzel M, Lommatzsch A, Bird A, Pauleikhoff D. Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD. *Eye (Lond)*. 2011 Sep;25(9):1181-6.
117. Introini U, Torres Gimeno A, Scotti F, Setaccioli M, Giatsidis S, Bandello F. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence. *Graefes Arch Clin Exp Ophthalmol*. 2012 Sep;250(9):1283-92.
118. Reche-Frutos J, Calvo-Gonzalez C, Pérez-Trigo S, Fernandez-Perez C, Donate-Lopez J, Garcia-Feijoo J. Ranibizumab in retinal angiomatic proliferation (RAP): influence of RAP stage on visual outcome. *Eur J Ophthalmol*. 2011 Nov-Dec;21(6):783-8.
119. Kim JH, Chang YS, Kim JW, Lee TG, Kim H. Diagnosis of type 3 neovascularization based on optical coherence tomography images.

120. Yannuzzi LA. Idiopathic polypoidal choroidal vasculopathy. Macula Society Meeting, 1982, Miami, FL.
121. Kleiner RC, Brucker AJ, Johnston RL. The posterior uveal bleeding syndrome. *Retina*. 1990;10:9-17.
122. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). *Retina*. 1990;10: 1-8.
123. Nakashizuka H, Mitsumata M, Okisaka S, et al. Clinicopathologic findings in polypoidal choroidal vasculopathy. *Invest Ophthalmol Vis Sci*. 2008;49:4729-4737.
124. Stern RM, Zakov ZN, Zegarra H, Gutman FA. Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. *Am J Ophthalmol*. 1985;100:560-569.
125. Yannuzzi LA, Ciardella A, Spaide RF, et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. *Arch Ophthalmol*. 1997;115:478-485.
126. Chang YC, Wu WC. Polypoidal choroidal vasculopathy in Taiwanese patients. *Ophthalmic Surg Lasers Imaging*. 2009; 40:576-58.
127. Ciardella AP, Donsoff IM, Huang SJ, et al. Polypoidal choroidal vasculopathy. *Surv Ophthalmol*. 2004;49:25-37.
128. Lafaut BA, Leys AM, Snyers B, et al. Polypoidal choroidal vasculopathy in Caucasians. *Graefes Arch Clin Exp Ophthalmol*. 2000;238:752-759.
129. Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Orlock DA. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. *Arch Ophthalmol*. 1997; 115: 478-85.
130. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlock DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. *Retina*. 1995; 15: 100-110.
131. Yuzawa M, Mori R, Kawamura A. The origins of polypoidal choroidal vasculopathy. *Br J Ophthalmol*. 2005; 89: 602-607.
132. MacCumber MW, Dastgheib K, Bressler NM, Chan CC, Harris M, Fine S et al. Clinicopathologic correlation of the multiple recurrent serosanguineous retinal pigment epithelial detachments syndrome. *Retina*. 1994; 14: 143-152.
133. Lafaut BA, Aisenbrey S, Van den Broecke C, Bartz-Schmidt KU, Heimann K. Polypoidal choroidal vasculopathy pattern in age-related macular degeneration. A clinicopathologic correlation. *Retina*. 2000; 20: 650-54.
134. Terasaki H, Miyake Y, Suzuki T, Nakamura M, Nagasaka T. Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation. *Br J Ophthalmol*. 2002; 86:321-27.
135. Rosa RH Jr, Davis JL, Eifrig CW. Clinicopathologic correlation of idiopathic polypoidal choroidal vasculopathy. *Arch Ophthalmol*. 2002; 120: 502-508.
136. Kuriwa S, Tateiwa H, Hisatomi T, Ishibashi T, Yoshimura N. Pathologic features of surgically excised polypoidal choroidal vasculopathy membranes. *Clin Exp Ophthalmol*. 2004;32:292-302.
137. Okubo A, Sameshima M, Uemura A, Kanda S, Ohba N. Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study. *Br J Ophthalmol* 2002;86:1093-98.
138. Nakajima M, Yuzawa M, Shimada H, Mori R. Correlation between indocyanine green angiographic findings and histopathology of polypoidal choroidal vasculopathy. *Jpn J Ophthalmol*. 2004; 48: 249-55.
139. Koh AH, Chen LJ, Chen SJ, Chen Y, Giridhar A, Iida T, Kim H, Yuk Yau Lai T, Lee WK, Li X, Han Lim T, Ruamviboonsuk P, Sharma T, Tang S, Yuzawa M; on behalf of the Expert PCV Panel. Polypoidal Choroidal Vasculopathy: Evidence-based Guidelines for Clinical Diagnosis and Treatment. *Retina*. 2013 Apr;33(4):686-716.
140. Lee MW, Yeo I, Wong D, Ang CL. Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy. *Eye (Lond)*. 2009;23:145-148.
141. Spaide RF, Donsoff I, Lam DL, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. *Retina*. 2002; 22(5):529-535.
142. E. Akaza, M. Yuzawa, Y. Matsumoto, S. Kashiwakura, K. Fujita, and R. Mori, "Role of photodynamic therapy in polypoidal choroidal vasculopathy," *Jpn J Ophthalmol*. 2007;51(4):270-277.
143. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. *Ophthalmology*. 2008;115(1):141-146.
144. Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. *Retina*. 2008;28(5):717-722.
145. Otani A, Sasahara M, Yodoi Y, et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. *Am J Ophthalmol*. 2007;144(1):7-e1.
146. Silva RM, Figueira L, Cachulo ML, Duarte L, Faria de Abreu JR, Cunha-Vaz JG. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. *Graefes Arch Clin Exp Ophthalmol*. 2005 Oct;243(10):973-9.
147. Kurashige Y, Otani A, Sasahara M, et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. *Am J Ophthalmol*. 2008;146(4):513-22.
148. Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. *Jpn J Ophthalmol*. 2011 Jan;55(1):39-44.
149. Kim SJ, Yu HG. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy. *Retina*. 2011; Oct;31(9):1827-34.
150. Lai TY, Chan WM, Liu DT, Luk FO, Lam DS. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. *Br J Ophthalmol*. 2008 May;92(5):661-6.

151. Eandi CM, Ober MD, Freund KB, Slakter JS, Yannuzzi LA. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. *Retina*. 2007 Sep;27(7):825-31.
152. Ricci F, Calabrese A, Regine F, Missiroli F, Ciardella AP. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy. *Retina*. 2012 Jul;32(7):1280-1288.
153. Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. *Retina*. 2012 Sep;32(8):1453-64.
154. Fernández M, Gil M, Gomez-Ulla F, Charlón P. Verteporfin photodynamic therapy combined with intravitreal ranibizumab for polypoidal choroidal vasculopathy controversy concerning long-term followup. *Case Rep Med*. 2012;2012:897097.
155. Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. *Am J Ophthalmol*. 2010 Nov;150(5):666-73.
156. Cheung CM, Yanagi Y, Mohla A, Lee SY, Mathur R, Chan CM, Yeo I, Wong TY. Characterization and differentiation of polypoidal choroidal vasculopathy using swept source optical coherence tomography angiography. *Retina*. 2016 Nov 8. 0:1-11 [Epub ahead of print].
157. Novais EA, Ferrara D, Waheed NK. Optical coherence tomography in polypoidal choroidal vasculopathy disease. *Clin Exp Ophthalmol*. 2015 Dec;43(9):779-81.
158. Inoue M, Balaratnasingam C, Freund KB. Optical coherence tomography angiography of polypoidal choroidal vasculopathy and polypoidal choroidal neovascularization. *Retina*. 2015 Nov;35(11):2265-74.
159. Kokame GT, Hirai K, Yanagihara R. Polypoidal Choroidal Vasculopathy: Imaging by Indocyanine Green Angiography and En Face Optical Coherence Tomography. *JAMA Ophthalmol*. 2015 Nov;133(11):e151886.

[View PDF](#)